These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35293200)

  • 1. Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study).
    Wybraniec MT; Maciąg A; Miśkowiec D; Ceynowa-Sielawko B; Balsam P; Wójcik M; Wróbel W; Farkowski M; Ćwiek-Rębowska E; Szołkiewicz M; Ozierański K; Błaszczyk R; Bula K; Dembowski T; Peller M; Krzowski B; Wańha W; Koziński M; Kasprzak JD; Szwed H; Mizia-Stec K
    Pol Arch Intern Med; 2022 Jun; 132(6):. PubMed ID: 35293200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study.
    Wybraniec MT; Wróbel W; Wilkosz K; Wrona K; Bula K; Mizia-Stec K
    J Am Heart Assoc; 2018 Oct; 7(20):e010153. PubMed ID: 30371270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II Study.
    Ceynowa-Sielawko B; Wybraniec MT; Topp-Zielińska A; Maciąg A; Miśkowiec D; Balsam P; Wójcik M; Wróbel W; Farkowski MM; Ćwiek-Rębowska E; Ozierański K; Błaszczyk R; Bula K; Dembowski T; Peller M; Krzowski B; Wańha W; Koziński M; Kasprzak JD; Szwed H; Mizia-Stec K; Szołkiewicz M
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department.
    Farkowski MM; Maciąg A; Żurawska M; Pytkowski M; Kowalik I; Woźniak J; Sterliński M; Szwed H
    Pol Arch Med Wewn; 2016 Jun; 126(6):381-7. PubMed ID: 27362390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid pharmacological cardioversion of recent-onset atrial fibrillation using antazoline in elderly patients.
    Farkowski MM; Maciąg A; Żurawska M; Kołakowski K; Gardziejczyk P; Kowalik I; Szwed H; Pytkowski M
    Pol Arch Intern Med; 2022 Jan; 132(1):. PubMed ID: 34643078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.
    Bonora A; Turcato G; Franchi E; Taioli G; Dilda A; Zerman G; Maccagnani A; Pistorelli C; Olivieri O
    Intern Emerg Med; 2017 Sep; 12(6):853-859. PubMed ID: 27384766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.
    Farkowski MM; Maciag A; Zurawska M; Kowalik I; Szwed H; Pytkowski M
    Cardiovasc Ther; 2018 Dec; 36(6):e12469. PubMed ID: 30281920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).
    Farkowski MM; Maciag A; Dabrowski R; Pytkowski M; Kowalik I; Szwed H
    Trials; 2012 Sep; 13():162. PubMed ID: 22967497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
    Maciag A; Farkowski MM; Chwyczko T; Beckowski M; Syska P; Kowalik I; Pytkowski M; Wozniak J; Dabrowski R; Szwed H
    Europace; 2017 Oct; 19(10):1637-1642. PubMed ID: 28339554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stunning of the left atrium after pharmacological cardioversion of atrial fibrillation.
    Zapolski T; Wysokiński A
    Kardiol Pol; 2005 Sep; 63(3):254-62; discussion 263-4. PubMed ID: 16180181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Valembois L; Audureau E; Takeda A; Jarzebowski W; Belmin J; Lafuente-Lafuente C
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD005049. PubMed ID: 31483500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland.
    Kiliszek M; Opolski G; Włodarczyk P; Dąbrowski R; Ponikowski P
    Cardiol J; 2014; 21(5):484-91. PubMed ID: 24526513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).
    Farkowski MM; Maciag A; Kowalik I; Konka M; Szwed H; Pytkowski M
    Br J Clin Pharmacol; 2019 Jul; 85(7):1552-1558. PubMed ID: 30920001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials.
    Ibrahim OA; Belley-Côté EP; Um KJ; Baranchuk A; Benz AP; Dalmia S; Wang CN; Alhazzani W; Conen D; Devereaux PJ; Whitlock RP; Healey JS; McIntyre WF
    Europace; 2021 Aug; 23(8):1200-1210. PubMed ID: 33723602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone.
    Fragakis N; Papadopoulos N; Papanastasiou S; Kozirakis M; Maligkos G; Tsaritsaniotis E; Katsaris G
    Pacing Clin Electrophysiol; 2005 Sep; 28(9):954-61. PubMed ID: 16176535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
    Chiou WR; Huang CC; Lin PL; Chuang JY; Liu LY; Su MI; Liao FC; Chen CY; Kuo JY; Tsai CT; Wu YJ; Lee YH
    Am J Cardiovasc Drugs; 2021 Jul; 21(4):459-469. PubMed ID: 33369716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which antiarrhythmic drug to choose after electrical cardioversion: A study on non-valvular atrial fibrillation patients.
    Gwag HB; Chun KJ; Hwang JK; Park SJ; Kim JS; Park KM; On YK
    PLoS One; 2018; 13(5):e0197352. PubMed ID: 29787592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis.
    De Vecchis R; Ariano C; Giasi A; Cioppa C
    Minerva Cardioangiol; 2018 Jun; 66(3):349-359. PubMed ID: 28497941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
    Chun KJ; Byeon K; Im SI; Park KM; Park SJ; Kim JS; On YK
    Clin Ther; 2014 Sep; 36(9):1169-75. PubMed ID: 25134972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.